IDH Inhibitor Ivosidenib Improve Overall Survival in Previously Treated Cholangiocarcinoma: ClarIDHy
- 3 years ago
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months compared with placebo in previously treated patients with advanced IDH1-mutated cholangiocarcinoma. Researchers presented results from the global phase III ClarIDHy trial at the 2021 Gastrointestinal Cancers Symposium (Abstract 266).
The favorable overall survival trend became statistically significant after adjusting for the 70% of patients crossing over to ivosidenib after radiographic disease progression. In that adjusted analysis, risk was reduced by 51% (P
The favorable overall survival trend became statistically significant after adjusting for the 70% of patients crossing over to ivosidenib after radiographic disease progression. In that adjusted analysis, risk was reduced by 51% (P